2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
---|---|---|---|---|---|---|---|---|---|---|
Sales - EUR | 255.294 | 308.895 | 391.736 | 458.842 | 474.416 | 507.898 | 499.365 | 501.434 | 601.976 | 3.596.281 |
Total Income - EUR | 257.545 | 308.897 | 391.737 | 459.328 | 482.795 | 526.148 | 499.368 | 501.438 | 601.980 | 3.596.346 |
Total Expenses - EUR | 258.245 | 283.066 | 360.630 | 393.605 | 410.574 | 467.316 | 472.132 | 445.453 | 519.074 | 2.897.756 |
Gross Profit/Loss - EUR | -700 | 25.831 | 31.107 | 65.723 | 72.221 | 58.832 | 27.235 | 55.985 | 82.906 | 698.590 |
Net Profit/Loss - EUR | -766 | 21.022 | 27.140 | 61.242 | 67.868 | 54.027 | 22.241 | 51.071 | 78.954 | 612.973 |
Employees | 18 | 20 | 22 | 26 | 24 | 23 | 24 | 24 | 24 | 23 |
Check the financial reports for the company - Nicomed Srl
2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
---|---|---|---|---|---|---|---|---|---|---|
Fixed Assets | 227.896 | 205.080 | 261.162 | 244.873 | 384.425 | 421.394 | 327.768 | 289.517 | 295.477 | 1.383.998 |
Current Assets | 6.363 | 2.179 | 2.030 | 11.194 | 16.609 | 19.332 | 26.162 | 27.907 | 31.877 | 118.514 |
Inventories | 5.725 | 10 | 656 | 1.174 | 629 | 2.213 | 11.210 | 13.934 | 13.182 | 18.036 |
Receivables | 0 | 0 | 0 | 2.121 | 1.131 | 1.064 | 3.692 | 2.441 | 633 | 2.509 |
Cash | 638 | 2.169 | 1.374 | 7.899 | 14.850 | 16.054 | 11.260 | 11.531 | 18.062 | 97.969 |
Shareholders Funds | 138.681 | 158.038 | 182.504 | 240.397 | 276.214 | 254.289 | 270.891 | 251.188 | 254.205 | 1.260.395 |
Social Capital | 67 | 67 | 66 | 64 | 63 | 62 | 61 | 61 | 61 | 300 |
Debts | 96.692 | 49.542 | 80.687 | 15.670 | 128.648 | 191.000 | 85.342 | 65.421 | 73.149 | 242.117 |
Income in Advance | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1.501 | 0 | 0 |
Exchange rate - RON | 1 | 4.9465 | 4.9315 | 4.9468 | 4.8371 | 4.7454 | 4.6535 | 4.5681 | 4.4908 | 4.445 |
Main CAEN | "8622 - 8622" | |||||||||
CAEN Financial Year |
8622
|
Subscriptions Financial Reports
You can check the financial situation of the companies in relation to the industry of which it is a part, credit limits and the risk of insolvency and suspension of accounts.
Comments - Nicomed Srl